Synthesis, characterization and in vitro studies of celecoxib-loaded poly(ortho ester) nanoparticles targeted for intraocular drug delivery

被引:21
作者
Palamoor, Mallika [1 ]
Jablonski, Monica M. [1 ,2 ]
机构
[1] Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA
[2] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA
关键词
Poly(ortho ester); Celecoxib; Nanoparticles; Solvent diffusion; Nile red; Cytotoxicity; CONTROLLED-RELEASE; BIOAVAILABILITY; SYSTEMS; PHASE; CELLS; ACID; FOOD;
D O I
10.1016/j.colsurfb.2013.07.039
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The present investigation is aimed at improving the ocular bioavailability of a poorly water soluble drug, celecoxib, to offer new options in the treatment of chronic eye diseases, such as age-related macular degeneration and diabetic retinopathy. To do so, we developed a novel formulation of drug-loaded poly(ortho ester) nanoparticles (NPs). We characterized the NPs in terms of size, morphology, controlledrelease, degradation and cytocompatibity. Stable and transparent NP emulsions were prepared following a double emulsion solvent diffusion method employing poloxamer 188 as a stabilizer. Physical properties showed a narrow range size distribution of 151-164 nm with spherical morphology, negative zeta potentials and remarkably high celecoxib encapsulation efficiency (98%) and loading (64%) of poly(ortho ester) NPs. Drug release followed a zero-order release by a surface erosion-controlled mechanism without any burst effect. Degradation of poly(ortho ester) NPs was observed by measuring the concentration of initial degradation product such as, lactic acid. MU studies revealed minimal toxicity of NPs (up to 1 mg/ml) toward HER 293 cells. Poly(ortho ester) NPs were not internalized by either Muller or HEK 293 cells, which is highly desirable for a drug carrier to deliver the drugs for prolonged periods to the back of eye. These features have the potential to decrease the number of intraocular injections required to treat chronic eye diseases. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:474 / 482
页数:9
相关论文
共 44 条
[1]   Transscleral drug delivery to the retina and choroid [J].
Ambati, J ;
Adamis, AP .
PROGRESS IN RETINAL AND EYE RESEARCH, 2002, 21 (02) :145-151
[2]   Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes [J].
Amrite, Aniruddha ;
Pugazhenthi, Vidya ;
Cheruvu, Narayan ;
Kompella, Uday .
EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (05) :631-645
[3]   Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism [J].
Amrite, Aniruddha C. ;
Kompella, Uday B. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 324 (02) :749-758
[4]   Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model [J].
Ayalasomayajula, SP ;
Kompella, UB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 511 (2-3) :191-198
[5]   Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model [J].
Ayalasomayajula, SP ;
Kompella, UB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 458 (03) :283-289
[6]   Effect of polymer compositions on the fabrication of poly(ortho-ester) microspheres for controlled release of protein [J].
Bai, XL ;
Yang, YY ;
Chung, TS ;
Ng, S ;
Heller, J .
JOURNAL OF APPLIED POLYMER SCIENCE, 2001, 80 (10) :1630-1642
[7]   Muller cells in the healthy and diseased retina [J].
Bringmann, Andreas ;
Pannicke, Thomas ;
Grosche, Jens ;
Francke, Mike ;
Wiedemann, Peter ;
Skatchkov, Serguei N. ;
Osborne, Neville N. ;
Reichenbach, Andreas .
PROGRESS IN RETINAL AND EYE RESEARCH, 2006, 25 (04) :397-424
[8]  
Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
[9]   Current and future ophthalmic drug delivery systems. A shift to the posterior segment [J].
del Amo, Eva M. ;
Urtti, Arto .
DRUG DISCOVERY TODAY, 2008, 13 (3-4) :135-143
[10]  
Einmahl S, 2001, INVEST OPHTH VIS SCI, V42, P695